Format

Send to

Choose Destination
See comment in PubMed Commons below
Mini Rev Med Chem. 2005 Dec;5(12):1125-32.

Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies.

Author information

1
Institut de Chimie Pharmaceutique Albert Lespagnol, Université de Lille 2, Lille, France. henicha@pharma.univ-lille2.fr

Abstract

This review presents some therapeutic interventions actually considered in prostate cancer therapy to compensate constitutive activation of the PI3K/Akt signalling pathway induced, particularly, by mutations of PTEN gene. Special emphasis is placed on applicability of EGF-R tyrosine kinase, COX-2, PDK-1, mTOR and farnesyltransferase inhibitors.

PMID:
16375758
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Bentham Science Publishers Ltd.
    Loading ...
    Support Center